ArticleCancers2013
The role of the immune response in merkel cell carcinoma.
Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Possible association between polyomaviruses and gastrointestinal complications: a narrative review.Gastroenterology and hepatology from bed to bench · 2024Review
- T-Cell Mediated Immunity in Merkel Cell Carcinoma.Cancers · 2022Review
- Merkel cell carcinoma in a young female on infliximab.JAAD case reports · 2022Article
- Treatment of locally advanced cutaneous Merkel cell carcinoma with topical imiquimod.JAAD case reports · 2021Article
- Spontaneous Regression of Merkel Cell Carcinoma: Case Report.International medical case reports journal · 2021Article
- Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.Endocrine pathology · 2020Article
- Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies.Frontiers in cell and developmental biology · 2019Review
- Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.Targeted oncology · 2018Review
- Avelumab: A Review in Metastatic Merkel Cell Carcinoma.Targeted oncology · 2018Review
- Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.Frontiers in medicine · 2018Review
- Merkel cell polyomavirus infection and Merkel cell carcinoma.Current opinion in virology · 2016Review
- Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma.Current oncology (Toronto, Ont.) · 2016Article
- Review
- The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancer.Viruses · 2015Review
- Spontaneous regression and recurrence of stage III Merkel cell carcinoma.BMJ case reports · 2015Article
- Mutational analysis of merkel cell carcinoma.Cancers · 2014Review
- Merkel cell carcinoma in immunosuppressed patients.Cancers · 2014Article
- Merkel Cell Carcinoma of the Head in a Young African Albino Woman with HIV/HTLV-1 Coinfection Associated with Multiple Squamous Cell Carcinomas.Case reports in dermatologyArticle
- The Disappearance of Lymph Node Metastasis from Neuroendocrine Carcinoma after Endoscopic Ultrasound-guided Fine Needle Aspiration.Internal medicine (Tokyo, Japan)Article
- Merkel cell carcinoma of the abdominal wall.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer. The Merkel cell polyomavirus (MCPyV) is implicated in its pathogenesis. Immune mechanisms are also implicated. Patients who are immunosuppressed have an increased risk. There is evidence that high intratumoral T-cell counts and immune transcripts are associated with favorable survival. Spontaneous regressions implicate immune effector mechanisms. Immunogenicity is also supported by observation of autoimmune paraneoplastic syndromes. Case reports suggest that immune modulation, including reduction of immune suppression, can result in tumor regression. The relationships between MCPyV infection, the immune response, and clinical outcome, however, remain poorly understood. Circulating antibodies against MCPyV antigens are present in most individuals. MCPyV-reactive T cells have been detected in both MCC patients and control subjects. High intratumoral T-cell counts are also associated with favorable survival in MCPyV-negative MCC. That the immune system plays a central role in preventing and controlling MCC is supported by several observations. MCCs often develop, however, despite the presence of humoral and cellular immune responses. A better understanding on how MCPyV and MCC evade the immune response will be necessary to develop effective immunotherapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.